Over 40 million Americans have reported using GLP-1 drugs for weight loss, a behavior reshaping everything from the healthcare industry to pop culture and consumer behavior—and the drugs’ use could balloon into as much as a $240 billion market.
While these weight-loss drugs pumped billions into pharma giants Eli Lilly and Novo Nordisk as social media and celebrity endorsements drove more people to buy them, the companies may not be the only ones to financially benefit. According to a new study released by the National Bureau of Economic Research (NBER), taking GLP-1s for obesity might also save middle-aged Americans hundreds of thousands of dollars in lifetime medical bills.
